Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Stroke often causes significant motor disability, especially hemiplegia, with many patients retaining movement difficulties six months after the event. Access to intensive rehabilitation after hospital discharge is often limited due to mobility, geography, and insurance issues. Telerehabilitation using digital tools offers a way to provide interactive, accessible therapy at home, with effectiveness comparable to in-person rehabilitation. This trial aims to evaluate a 12-week home-based telerehabilitation program using the MindMotion GO device, providing extra therapy alongside standard care for stroke patients in sub-acute and chronic stages. Participants will use the MindMotion GO device at home for at least 300 minutes of active therapy weekly during the 12-week program. They will have one weekly live session with a physical or occupational therapist either in clinic or remotely by videoconference, combined with independent sessions guided by a personalized schedule set by a remote therapist. The study compares two groups one starting telerehabilitation immediately after discharge alongside standard care, and another receiving standard care first, then starting telerehabilitation after 12 weeks. Patients may continue the telerehabilitation beyond 12 weeks if they choose. Throughout the study, researchers will monitor participants progress using the Goal Attainment Scale at several timepoints up to 44 weeks. Assessments will include therapy adherence, motor function improvements, and the feasibility of the home-based program. Patients will transition smoothly from hospital to home rehabilitation without extending hospitalization or increasing in-person visits. The total study duration for participants may extend up to 44 weeks to evaluate both short- and longer-term effects.
Actively Recruiting
Researchers are evaluating the impact of local vibration therapy on the recovery of walking ability in patients who have experienced a stroke in the recent subacute phase. The study compares standard rehabilitation alone with the addition of vibration sessions applied to the dorsiflexor muscles of the affected leg. This research aims to determine if these vibrations can improve walking speed, with a randomized controlled design including an experimental group receiving vibration and a control group receiving sham vibration. Participants will undergo 40 sessions of treatment over 8 weeks during their hospital stay, with five sessions per week. The experimental group will receive effective vibrations at a frequency of 100 Hz applied locally to the dorsiflexor muscles, while the control group will receive sham vibration without actual stimulation. Both groups will continue to receive standard post-stroke rehabilitation. During the study, participants walking speed will be measured using the 10-meter Walk Test at two months as the primary outcome. Additional assessments include longer distance walking tests, detailed gait analysis, motor function evaluation, muscle spasticity, walking autonomy, lower limb strength, and neuromuscular fatigue. These evaluations will take place at various time points up to four months to monitor recovery progress and safety, with the entire study expected to last until May 2029.
Actively Recruiting
Researchers are evaluating the impact of an individual peer support intervention for patients recovering from a stroke as they return home. The study aims to see if personalized support from trained patient-partners can improve quality of life and empower patients during the discharge period compared to usual care. This pilot study considers the challenges patients and families face with shortened hospital stays and the need for emotional and social support at home. Participants in the intervention group will receive peer support from trained peers for six months after discharge, with the frequency and number of contacts tailored to each patients needs. This support includes meetings before discharge and ongoing follow-up through face-to-face, virtual, or phone contact, focusing on helping patients manage their situation and connect with health and social resources. The control group will receive standard care and be contacted for data collection six months after returning home. Throughout the study, patients will be assessed on various measures including feasibility, quality of life, anxiety and depression, patient activation, disability, adherence to care, assistance received at home, satisfaction, and caregiver burden and satisfaction. Data collection will occur over a six-month period after discharge. This approach aims to understand how peer support affects both patients and their caregivers during recovery at home.
Actively Recruiting
This research focuses on adults who have experienced a stroke resulting in hemiparesis and spastic foot conditions such as equinovarus and toe claw due to muscle spasticity. The study compares two treatments tibial nerve selective neurotomy STN and botulinum toxin A BoNT-A injections. It aims to determine which treatment better reduces calf muscle spasticity and improves personal goals related to balance, walking, self-care, and quality of life for patients with post-stroke spastic foot. Participants are randomly assigned to one of two groups. The STN group will undergo surgery within three months after enrollment, targeting specific muscles defined before randomization. The procedure lasts about 90 minutes and requires a pre-anaesthetic evaluation. The BoNT group will receive botulinum toxin injections guided by electromyography, electrical stimulation, or ultrasound. Physicians may choose between two approved botulinum toxin formulations and determine the dosage and targeted muscles based on clinical guidelines and experience. Treatments are spaced at least three months apart. Throughout the 14-month study, participants will be assessed for progress toward personal goals using the Goal Attainment Scaling. Researchers will also evaluate functional outcomes, spasticity severity, ankle motion, pain levels, walking speed and distance, use of antispastic medication, adverse events, and patient satisfaction. These assessments aim to provide a comprehensive understanding of the impact of each treatment on spastic foot symptoms and daily living activities after stroke.
Actively Recruiting
Researchers are evaluating the EXOPULSE Suit, a medical device designed to stimulate multiple muscle groups to help relax tense and spastic muscles, in people with Multiple Sclerosis MS. The study aims to confirm whether this device can improve walking ability compared to a sham version. This research is important for individuals with MS who experience reduced mobility and may not be able to use drug treatments like Fampridine due to side effects or other reasons. The EXOPULSE Suit is a wearable device with 50 electrodes that stimulate up to 43 major muscle groups. Participants will use the suit for one hour every other day at home. The study uses a randomized crossover design where participants first use the active suit for 4 weeks, then have a 4-week washout period, followed by 4 weeks using the sham suit, or vice versa. The sham suit provides stimulation only during the first minute, then turns off. During the study, participants will be assessed through various tests including walking scales, timed walk tests, and fatigue and pain questionnaires over 28-day periods. Researchers will monitor walking ability and muscle spasticity, among other outcomes. Participants must attend all medical visits and will be monitored throughout the study, which starts in March 2026 and continues until March 2027.
Actively Recruiting
This research focuses on adults with bilateral traumatic amputation of both forearms, a rare condition that greatly affects independence and quality of life. The study evaluates two approaches bilateral hand and forearm allografts transplants and the use of prosthetic forehands. It aims to compare these options in terms of costs, quality of life, usefulness, satisfaction, autonomy, and social integration. The study builds on previous work that demonstrated the feasibility and functional benefits of bilateral hand grafts, despite the need for immunosuppressive treatment and potential medical complications. Participants receive either a bilateral allograft of the hands and forearms or prosthetic forehands. The transplant group must meet specific medical and psychological criteria, including a minimum of three months since amputation and no recent cancer history. The prosthetic group uses prosthetic devices for limb replacement. This non-randomized study conducted by Hospices Civils de Lyon compares these two treatment approaches over a 36-month period. During the study, researchers will monitor treatment costs over 36 months as the primary outcome. Participants will be assessed for quality of life, autonomy, satisfaction, and social integration. Medical evaluations include psychological assessments, kidney function, heart function, and blood pressure control for the transplant group. The study runs until October 2031, and participants will be regularly evaluated to understand the long-term impact and benefits of each treatment option.
Actively Recruiting
Researchers are studying patients with Post-Acute COVID-19 Syndrome who have ongoing or complex symptoms lasting more than 4 weeks or 3 months after documented SARS-CoV-2 infection. The study aims to identify clinical profiles of these long-COVID patients and link them with immunological and molecular data to find prognostic biomarkers and possible treatment targets. Participants are adults aged 18 years or older who join either a post-COVID rehabilitation program or the EPSILON care pathway. During a single inclusion visit, clinical and biological data are collected, including a one-time 30 mL blood sample for immunological and molecular analysis. No therapeutic intervention is given, and samples are analyzed without storage after testing. During the visit, researchers gather detailed clinical and biological information to classify participants into clinical clusters based on symptoms and other data. They measure residual viral proteins and serum biomarkers to understand differences between patient groups. The main outcome is the number of participants in each clinical cluster at the time of inclusion. The study monitors patients profiles at this single time point, with no long-term follow-up specified. The study is led by Hospices Civils de Lyon and will run until June 2026.